Oligo Medic a été fondée en 2010 par des experts en biomatériaux qui ont développé les premiers implants thermogélifiants à base de polysaccharides pour applications biomédicales, avec la vision de fournir des solutions minimement invasives intégrées sans encombre dans les pratiques cliniques.

La technologie principale de la compagnie consiste en une composition gélifiante avec les charactéristiques suivantes:

  • Biocompatible: elle peut être administrée n'importe où dans le corps sans éliciter quelque réaction adverse du tissu que ce soit. Son pH et son osmolarité sont physiologiques, et elle permet une excellente viabilité cellulaire.
  • Thermogélifiante: Appliquée par aiguilles standard, elle solidifie à la température du corps. Ceci lui permet d'être administrée en tant qu'implant sans avoir recours à une implantation chirurgicale ou encore e.g. le crosslinking UV.
  • Bioadhésive: Dû à des charges au niveau moléculaire, elle adhère aux surfaces muqueuses de façon électrostatique, permettant une application précise à l'endroit désiré, sans avoir recours à de la fibrine ou autre agent collant.
  • Biodégradable: Une fois à l'intérieur du corps, elle se dégrade lentement en les molécules qui la composent, qui se retrouvent naturellement dans le corps humain.

Ces propriétés en font un implant idéal pour traiter les lésions du cartilage articulaire. La perte du cartilage est un problème majeur et courant qui peut avoir à l'origine l'ostéoarthrite ou les événements traumatiques. Ce besoin clinique important est adressé principalement par le remplacement total de l'articulation (prothèse) et d'autres procédures coûteuses/invasives. Les approches préventives, incluant la viscosupplémentation (injections d'acide hyaluronique) ont démontré un succès limité.

Oligo Medic a concentré ses efforts à développer son premier produit JointRepTM comme solution minimalement invasive pour la perte de cartilage. Elle a obtenu pour ce dernier le marquage CE en 2013 et le fabrique et commercialize présentement pour plusieurs marchés à travers l'Europe, l'Amérique Latine, le Moyen-Orient, l'Asie du Sud-Est et la Nouvelle-Zélande. La compagnie prépare également un essai clinique pour JointRepTM aux États Unis.

Oligo Medic opère sous un Système Qualité qui concorde avec les normes ISO 13485:2016.

La compagnie a entamé un projet qui vise à utiliser sa technologie pour adresser la dégénération du disque intervertébral. D'autres projets futurs incluent l'administration localisée de cellules souches pour d'autres applications en médecine régénérative, administration localisée de médicaments, la guérison de plaies, la cosmétique, et d'autres.

1 Chenite A, Chaput C, Combes C, Selmani A, Jalal F. Temperature-controlled pH-dependent formation of ionic polysaccharide gels US Patent 6,344,488. Feb 5, 2002

2 Chenite A, Selmani A. Highly Biocompatible Dual Thermogelling Chitosan/Glucosamine Salt Compositions. US Patent 8,506,972. Mar 1, 2012

News and Updates

2019
Obtention de l'approbation de la TGA pour JointRep™ en Australie.

2018
Obtention de l'approbation de Santé Canada pour JointRep™.

2018
Étapes préliminaires entamées en vue d'obtenir une approbation de la FDA pour le marché des États-Unis.

2018
Gain de pénétration de marché en Europe, Australie et Nouvelle-Zélande, Moyen-Orient, Asie du Sud Est et en Amérique Latine.

2018
Résultats très favorables de l'étude clinique publiés dans le Journal of Clinical Orthopedics and Trauma.

2017
D'autres études cliniques sur différentes indications sont planifiées et seront divulguées lorsque les protocoles seront définis.

2015
Étude clinique contrôlée initiée en Europe: 69 patients, et comparaison de microfracture à microfracture & JointRep™.

2014
Expérimentation initiale avec JointRep™ et microfracture. Les résultats sont hautement favorables avec soulagement rapide de la douleur, temps de recouvrement accéléré, et belle croissance de cartilage.
2013
Structuration d'OligoMedic pour partenariat de distribution et initiation d'études cliniques et évaluation post-marché
2012
Définition de processus de manufacture, emballage, et transport. Marquage CE obtenu en octobre.

2011
Poursuite de série de cas sous le programme SAP de Santé Canada.

2010
Création d'Oligo Medic Inc. Développement de plateforme technologique et charactérisation pré-clinique. Initiation du programme SAP de Santé Canada. Première opération humaine avec JointRep™ avec succès.

Management Team

Amine Selmani, PhD

Executive Chairman
Dr. Amine Selmani holds a PhD in Material Sciences (1985) from the University of Montreal. After three years as post-doc positions in different universities, he joined the prestigious engineering school ‘Ecole Polytechnique de Montreal’ as a Professor. Dr. Selmani’s research in biomaterials and biotechnologies led him to incorporate BioSyntech in 1995 and be part of its executive team as CEO and Chairman of the Board for close to 10 years (1995-2004). During his tenure, Dr. Selmani was able to take this biotechnology company public on both Nasdaq and TSX.

More…

Also, Dr. Selmani founded in 1992 POLNOR (Polytechnique-Noranda) group of around 30 engineers and professionals, with the mandateto provide higher value to the Noranda amorphous silicon and other products (produced in very small quantities). Big budgets coming from Noranda, Natural Sciences and Engineering Research Council of Canada, 3M and The Ecole Polytechnique de Montreal allowed the development of High Resolution Digital Mamograph X-rays plates that are today used in most of radiology centers and commercialized by the well-known company in the field, Analogic. Few employees coming from the same project created a company (5N Plus), now leader in the world of high-specialized materials. The company is listed on the TSX, Toronto.

Jerett Creed

Chief Executive Officer
Mr. Creed has more than 20 years of medtech experience spanning multiple disease sectors and leadership roles with a strong focus on international commercialization, capital markets and business development. Mr. Creed has participated in a leadership role on transactions exceeding $650 million in M&A activity including 2 public offerings. Most recently Mr. Creed was in charge of launching Oligo Medic's JointRep™ product throughout Latin America. Prior to that, Mr. Creed was founder and CEO of Cardigant Medical, a formerly public company focused on the development and commercialization of novel peptide mimetics for treating vascular disease. Before that Mr. Creed was interim Chief Financial Officer for a publicly traded oil and gas company providing leadership through multiple acquisitions and one divestiture. Mr. Creed began his career with Johnson and Johnson initially focused on manufacturing and product development of early angioplasty balloons and bare metal stents ultimately spending more than a decade with the company finishing his tenure as Director of Business Development for an internally funded stem cell based incubator. Mr. Creed holds a Master of Science degree in Accounting and a Bachelor of Science degree in Engineering both from the University of Miami.

Abdellatif Chenite, PhD

Chief Technology Officer
Dr Chenite has the distinction of being co-founder of Oligo Medic and inventor of its technology platform. He successfully led the first company product from conception through to manufacturing completion. Dr Chenite is an accomplished scientist and inventor, with many patents and relevant publications, focused on the development of innovative biomaterial devices for biomedical technologies. His impressive array of knowledge and technology skills is a real asset for the company.

More…

Dr Chenite obtained a Ph.D. in Polymer Chemistry, in1992, from the University of Montréal, and immediately after his graduation he was hired a Research Associate at the National Research Council, in Ottawa, Canada, where he worked during 3 years. In 1996, he joined Biosyntech as research director and he was an essential contribution to the company success by inventing BST-Gel technology platform early in 1998. He has published more than 35 peer-reviewed scientific articles and authored patent applications for numerous distinct inventions.

Cyril Chaput, PhD, MBA

VP RA/QA
Cyril Chaput, PhD, MBA,has more than 15 years of experience as a manager in Life Science and Biotechnological companies. Cyril Chaput has biomedical engineering and biomaterials background, and holds several patents and scientific publications. He has been involved in R&D, intellectual property management, product management and business development in various Biotech and medical technology companies.

More…

Cyril Chaput has been involved in the Biomaterial platforms development at Bio Syntech Canada, and has been IP and Business Development manager and Product manager for the Medical Device company, Angiogene Inc. In addition to his extensive work experience, Mr. Chaput holds a PhD in biomedical engineering from the EcolePolytechnique de Montreal, and a MBA in Bio-industries Management from the UQAM in Canada.

Alberto Restrepo, MD

Chief Medical Officer
Alberto Restrepo, MD
Chief Medical Officer

Dr. Restrepo is an Orthopaedic Surgeon who after more than 20 years of a successful career as an arthroscopic surgeon, vice dean of the Universidad de La Sabana Medical School in his native Bogota (Colombia), Executive Secretary and Board member for the Colombian Orthopaedic Association (SCCOT) for several years, and KOL and international lecturer for Howmedica, Stryker and Genzyme in the domains of external fixation, bone lengthening, viscosupplementation and cartilage repair, was appointed in October 2005 by the start-up called BioSyntech (issued from the Ecole Polytechnique de Montreal) to set up and manage the Medical Affairs of the company. He contributed with his medical expertise and management skills to the success of the project BST-CarGel on cartilage repair. After its acquisition by Piramal Life Sciences, he managed both the clinical and medical departments. He was part of the reduced management team who successfully obtained the CE Mark, Canadian, Australian as well as other countries approval for the chitosan based product BST-CarGel, as well as its reimbursement in several countries. He had a pivotal role in the two Level 1 successful RCTs for cartilage repair with BST-CarGel. He set up the medical networking for its commercialization in Europe, Canada, LATAM, India and Australia/New Zealand, and participated actively in the team which designed the marketing and training strategies to introduce the technology worldwide. He is fluent in English, French and Spanish (his mother tongue). Dr. Restrepo also holds a degree in Medical Education from Universidad de La Sabana (2002) and a PDD (Programa de Desarrollo Directivo) from INALDE Business School (1999). His network of colleagues includes top KOLs in Canada/USA, Europe, LATAM, India and Australia/New Zealand.

Monique Jarry

VP Finance & Human Resources
Mrs. Monique Jarry
VP Finance & Corporate Development

Ms Jarry holds a BA and MA (1991) from University of Montreal. She implemented many accounting systems in public companies listed in Nasdaq BB and on TSX. Ms. Jarry supervised all the financial aspects of a private investment company from 1992 until 2010, when she joined Oligomedic as a VP Finances.

Sam Alexandre Selmani, Ph.D

VP Product Development